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Results: A total of 1847 pts (904 right-sided and 943 left-
sided) were treated with either 40 Gy/15 fx (912 pts) or 50 
Gy/25 fx (935 pts). 388 of the left-sided pts were treated 
with gated RT, and 440 without. No information about gating 
was available for the remaining 115 pts. Dmax(CTV) was less 
than 110% of the prescription dose in 99.4% of the plans. 
More than 2 cm3 of the CTV received 107-110% of the dose in 
1% of the hypo-fractionated plans. For the normo-
fractionated plans, this deviation was observed in 3.5% of the 
plans. For 92.3% of the hypo-fractionated plans, less than 2% 
of the CTV was covered with doses above 105%, whereas 3.9% 
and 3.5% of the plans had minor and major deviations, 
respectively. For 80.8% of the pts, the part of the CTV 
covered with at least 95% of the prescription dose was in 
compliance with the guidelines. Minor and major deviations 
were observed for 12.6% and 6.6% of the pts, respectively. By 
taking laterality into consideration, 90.8% of the right-sided 
pts were in compliance with the guidelines compared to only 
71.2% of the left-sided pts. For the left-sided pts with 
available information about gating, it was found that 87.4% 
and 59.3% of the pts treated with and without gated RT, 
respectively, were in compliance, thus indicating that 
shielding of the heart resulted in CTV under-dosage. This was 
supported by compliance to the protocol heart dose 
guidelines for 941 left-sided pts. Only one hypo-fractionated 
pt showed a major deviation in V35Gy and a minor deviation 
in V17Gy (data missing for one pt). The lung dose satisfied 
the protocol guidelines for 99.4% of the pts.  
 
Conclusion: A high degree of compliance with protocol 
guidelines was found for the DBCG HYPO trial. Only a few pts 
received CTV doses above 107% of the prescription dose. The 
CTV volume covered with less than 95% dose deviated from 
protocol guidelines for about 40% of the left-sided pts treated 
without gated RT. With gated RT this number decreased to 
about 12%, almost equal to that of right-sided pts. This 
indicates that gated RT for left-sided pts reduces the 
necessity of CTV dose compromise due to heart shielding. 
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Purpose or Objective: Stereotactic ablative radiotherapy 
(SABR) is routinely used for the treatment of early stage lung 
cancer and is increasingly used to treat other primary tumour 
sites. There are currently 6 UK studies (of which 3 are 
randomised) investigating the utility of SABR in the treatment 
of oligometastatic disease (breast, lung, prostate), lung, 
prostate, pancreas and hepatobiliary primary malignancies. 
These are supported by CRUK and currently open or in set-up 
to begin recruitment in 2016. In addition, a NHS 
Commissioning Through Evaluation (CTE) programme was 
commenced in 2015 to evaluate SABR in situations where 
clinical trials are not available. In an attempt to standardise 
protocols and the associated radiotherapy planning we sought 
to generate consensus normal tissue dose constraints 
tolerances across these UK studies. 
 
Material and Methods: Members of the various SABR studies' 
trial management groups, facilitated by the UK Radiotherapy 
Trials Quality Assurance Group (RTTQA), met to generate a 
unified table of normal tissue dose constraints. As a starting 
point, the UK SABR Consortium Guidelines, the AAPM TG-101 
report and other seminal publications were used to define a 
baseline reference. These initial constraints values were 
revised, where appropriate, by taking into consideration any 
updated or more robust data that better informed a given 
dose constraint value in the opinion of the panel.  
 
Results: Following an iterative process, agreement was 
reached on all dose constraints covering the central nervous 
system, thorax, abdomen, pelvis, skin and bone. It was 
agreed to use a point maximum dose volume of 0.5cc for the 
purposes of describing the maximum dose for all organs 
except the spinal cord. For the spinal cord 0.1cc is to be 
used. The group reached the consensus that for the purpose 
of these trials single fraction should not be used outside CNS. 
We recommended the use of 3, 5 and 8 fractions regimes. 
These dose constraints will be used for the forthcoming SABR 
studies and for the implementation of the CTE SABR 
programme for oligometastatic disease and HCC. The group 
will review the evidence annually to update the guidelines. 
 
Conclusion: A UK national agreement on SABR dose 
constraints has been successfully achieved. It is hoped that 
this unified approach will facilitate standardised 
implementation of SABR across the UK and will permit 
meaningful toxicity comparisons between SABR studies and 
further refinement of the constraints. Any further trials 
developed in the UK will adopt the consensus. 
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Purpose or Objective: The BSD-2000/3D system (BSD Medical 
Cooperation, Salt Lake City, USA) is used to treat deep 
seated tumors with hyperthermia (to temperatures of 41-
43°C) in combination with radiotherapy. Treatment planning 
for this system is done with the software SigmaHyperplan (Dr. 
Sennewald Medizintechnik GmbH, Munich, Germany). In this 
study a method and first results for pre-treatment 
verification of clinical patient treatment plans using a 3D SAR 
scanning phantom developed at the Kantonsspital Aarau are 
presented. 
 
Material and Methods: Treatment plans for individual 
patients were generated with SigmaHyperplan and applied to 
a saline phantom model. The result is a set of data for the 
